

REMARKS

Claims 1, 3-7, 9-10, 12-13, 15-18, 22-26, and 34-39 are pending in the application.

Applicants elect without traverse Group III (claims, in part, 1-13, 15-18, 21-28, and 34-39), drawn to a compounds of Formula I where each Z represents C, ring B represents 5-membered saturated carbocyclic ring, X represents C₁₋₅alkylene chain without heteroatoms and ring A represents a tropane ring connected to X via N atom (see compounds on page 35 of the specification), pharmaceutical compositions containing these compounds and methods of treatment using these compounds. Applicants have amended the claims to cancel non-elected subject matter in response to the restriction requirement. Applicants may file one or more divisional applications to the non-elected subject matter.


Since restriction to Group III has been selected, Applicants make the following species elections: Z is C; ring B is a 5-membered saturated carbocyclic ring, X is a C1-5 alkylene having 0 heteroatoms, and ring A is tropane connected to X via a N atom. To further assist the Examiner, attention is directed to Claim 1 as amended and Example 45 in the specification (WO 2004/055012 at page 73).

Claims readable on the elected species are claims 1, 3-7, 9-10, 12-13, 15-18, 22-26, and 34-39.

Reconsideration of the application in view of the amendments to the claims and remarks following is earnestly solicited.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 14 May 2008
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988